ArticleAmerican journal of hematology2013
The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma.
Article in American journal of hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06931652 (A Phase 2 Study Evaluating Epcoritamab in Subjects With Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab), which is not on this map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Study Evaluating Epcoritamab in Subjects With Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Who cites it
68 citing papers in PubMed, 144 citations in OpenAlex.
- Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.Hematological oncology · 2020Trial
- Nationwide Incidence, Treatment Pattern, and Prognosis of Primary CNS Lymphoma in Taiwan, 2012-2020: A Retrospective Cohort Study.Cancer medicine · 2026Article
- Educational and regional differences in population-based incidence and survival of primary central nervous system lymphoma in Finland.BMC cancer · 2026Article
- Review
- Article
- Article
- Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphoma.Blood advances · 2024Article
- Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET/CT.Neuro-oncology · 2024Article
- Article
- MRI-Based Machine Learning for Prediction of Clinical Outcomes in Primary Central Nervous System Lymphoma.Life (Basel, Switzerland) · 2024Article
- Molecular Analysis of Liquid Vitreous Biopsy Reveals Occult Lymphoma Following Cytology-Negative Biopsies of the Brain and Vitreous.Ocular immunology and inflammation · 2024Article
- Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma.Journal of clinical medicine · 2024Article
- Article
- Primary central nervous system lymphoma.Journal of neurology · 2024Review
- Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.Japanese journal of ophthalmology · 2023Review
- Improving the Classification of PCNSL and Brain Metastases by Developing a Machine Learning Model Based onJournal of personalized medicine · 2023Article
- European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).Neuro-oncology · 2023Article
- High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.Journal of Cancer · 2023Article
- Pretreatment diffusion-weighted imaging for prediction of relapsed and refractory primary central nervous system lymphoma.Frontiers in neurology · 2023Article
- Central Nervous System Lymphoma: The Great Mimicker-A Single-Institution Retrospective Study.Case reports in oncological medicine · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
There has been an overall decline in the United States incidence of Primary CNS Lymphoma (PCNSL) from 1998 to 2008. This study's intent was to characterize the cohorts contributing to it. First, calculated the PCNSL incidence rates from nine Surveillance, Epidemiology, and End Results (SEER) registries for time period 1973 to 2008. Second, examined the time trends overall and by age and gender. Third, used 1992-2008 SEER data from the same registries to obtain overall trends for diffuse large B-cell lymphoma (DLBCL). Last, rates were age-adjusted to the 2000 US standard population and reported per 100,000 person-years. Rates continued to increase in women at all ages and men aged 65 and older. In men aged 20-39 and 40-64 years incidence rates peaked in 1995 and then declined dramatically, stabilizing after 1998. The trends in the incidence of PCNSL over this time frame were significantly different from DLBCL for ages 20-39 (P < 0.001) and 40-64 (P < 0.001) years but were not different for the 65 years and older age group (P = 0.99). The overall PCNSL incidence rate declined since 1995 and was driven primarily by the changing incidence in young and middle-aged men. The rate has continued to increase in men aged 65 years and older and in women. The trends in incidence in the younger age groups over this time period did not parallel those observed for DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.